From the clip:
“We are excited to test sozinibercept in large P3 programmes […] with the goal of […] showing that we can improve visual acuity hopefully by up to 5 letters or more.“
To my memory, this is the first time somebody sharing responsibility for running the trials dares to explicitly mention a „5 letters or more“ improvement as what OPT internally is really hoping for. If this hope materializes then Eichenbaum is absolutely right saying that sozinibercept would disrupt the wAMD market.
I just cannot believe existing players continuing to stay quiet with this disruptive opportunity being up for sale / partnership just 15 months ahead of P3 results. Therefore, I’d indeed expect a partnership occurring over the next 3 months being more probable than a classic CR.
- Forums
- ASX - By Stock
- OPT
- Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-42
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
36.5¢ |
Change
0.005(1.39%) |
Mkt cap ! $398.3M |
Open | High | Low | Value | Volume |
36.0¢ | 37.5¢ | 34.5¢ | $755.3K | 2.117M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 27776 | 36.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.0¢ | 13607 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 27776 | 0.365 |
6 | 61904 | 0.360 |
3 | 262324 | 0.355 |
11 | 401285 | 0.350 |
8 | 326491 | 0.345 |
Price($) | Vol. | No. |
---|---|---|
0.370 | 13607 | 7 |
0.375 | 15221 | 1 |
0.380 | 25566 | 3 |
0.385 | 167477 | 6 |
0.390 | 7694 | 2 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |